newsfilter
← Latest News
Business Wire·

Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes

The company plans to advance the licensed GLP-1/gastrin dual-agonist peptide portfolio from Zealand Pharma as a disease-modifying therapy to regenerate and protect endogenous beta-cell mass in patients with type 1